Tesamorelin
Also known as: Egrifta, TH9507, GHRH analog
Synthetic GHRH analog FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy.
Benefits
6
Conditions
5
Evidence
Phase 3 trials, FDA approved for HIV lipodystrophy+ studies
Source
Synthetic GHRH analog with trans-3-hexenoic acid modification
Gabriel Brain Score
Strong
Overview
Synthetic GHRH analog FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy.
Mechanism of Action
Binds GHRH receptors on pituitary somatotrophs, stimulates pulsatile GH release, increases IGF-1, preferentially reduces visceral fat via GH-mediated lipolysis, minimal effect on subcutaneous fat.
Key Benefits
- ✓Reduces visceral adipose tissue
- ✓Improves body composition
- ✓Increases lean muscle mass
- ✓Enhances GH and IGF-1 levels
- ✓Improves lipid profiles
- ✓Cognitive benefits (emerging data)
Clinical Applications
Dosing Guidelines
Subcutaneous injection
* Dosing should be individualized. Always consult with a qualified healthcare practitioner.
Research & Evidence
Phase 3 trials, FDA approved for HIV lipodystrophy
FDA approved based on trials showing 15-20% visceral fat reduction. Strong evidence for body composition improvement. Emerging research for cognitive enhancement in mild impairment.
Safety Information
Potential Side Effects
- •Injection site reactions
- •Arthralgia
- •Peripheral edema
- •Muscle pain
- •Elevated IGF-1
- •Glucose intolerance
Contraindications
- Active malignancy
- Diabetic retinopathy
- Pregnancy
- Breastfeeding
- Pituitary tumor
Interactions
- ⚠May affect glucose metabolism
- ⚠Monitor with diabetes medications
Quick Facts
Related Peptides
Hexarelin
Potent hexapeptide ghrelin mimetic with strong GH-releasing effects and cardioprotective properties.
CJC-1295
Long-acting GHRH analog that stimulates sustained growth hormone release.
Sermorelin
Short-acting GHRH analog that stimulates natural pulsatile growth hormone release from the pituitary.